Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jul;56(7):4018-20.
doi: 10.1128/AAC.06474-11. Epub 2012 Apr 23.

Etravirine concentrations in the cervicovaginal compartment in HIV-1-infected women receiving etravirine-containing antiretroviral therapy: DIVA 02 study

C Clavel  1 , G Peytavin, R Tubiana, C Soulié, E Courbon, C Crenn-Hebert, H Ichou, C Blanc, L Schneider, C Katlama, A-G Marcelin, L Mandelbrot
Affiliations

Etravirine concentrations in the cervicovaginal compartment in HIV-1-infected women receiving etravirine-containing antiretroviral therapy: DIVA 02 study

C Clavel et al. Antimicrob Agents Chemother. 2012 Jul.

Abstract

We studied the penetration of etravirine and HIV shedding in the genital tract among 12 HIV-1-infected women receiving an etravirine-containing regimen who had <40 copies/ml blood plasma (BP) HIV RNA. None of the cervicovaginal fluid (CVF) samples showed detectable HIV RNA. Median etravirine concentrations were 663 ng/ml in BP and 857 ng/ml in CVF, with a CVF/BP etravirine ratio of approximately 1.2. This good penetration of etravirine may contribute to the control of viral replication in the female genital tract.

PubMed Disclaimer

References

    1. Clavel C, et al. 2011. Raltegravir concentrations in the genital tract of HIV-1-infected women treated with a raltegravir-containing regimen (DIVA 01 Study). Antimicrob. Agents Chemother. 55:3018–3021 - PMC - PubMed
    1. Cu-Uvin S, et al. 2010. Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load. AIDS 24:2489–2497 - PubMed
    1. Cu-Uvin S, et al. 2000. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS 14:415–421 - PubMed
    1. De Pasquale MP, et al. 2003. Differences in HIV-1 pol sequences from female genital tract and blood during antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 34:37–44 - PubMed
    1. Dumond JB, et al. 2009. Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women. J. Acquir. Immune Defic. Syndr. 51:546–553 - PMC - PubMed

Publication types